Anzeige
Mehr »
Login
Sonntag, 26.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
291 Leser
Artikel bewerten:
(1)

LoanStream Mortgage: LoanStream Continues to Break Barriers and Releases New Proprietary Products

Finanznachrichten News

Bucking the current market trends of receding guidelines, staffing layoffs and lower production, LoanStream continues to surprise with its consistent approach of providing all methods of financing to a shrinking mortgage market.

IRVINE, CA / ACCESSWIRE / September 6, 2023 / It's no surprise that the mortgage market is contracting significantly, thanks to the Federal Reserve's approach to battle inflation with higher interest rates. LoanStream continues to provide innovative options while ensuring each consumer's ability to repay. In the world of affordability, the Federal Reserve leaves us with much to be desired and interpreted. "Our mission is to ensure a suite of loan program options to navigate any market, even this one," said Rabi Aziz, LoanStream's Chairman and CEO.

In its first September debut, LoanStream will now offer a proprietary Closed-End 2nd TD program on all income doc types, including DSCR loans. Borrowers with mortgage rates established in 2020-2021, with rates in the 2-4% range are unlikely to refinance those low-rate loans. Giving them the option of a 2nd TD will offer a much lower blended interest rate scenario than refinancing the 1st TD into today's high interest rates. Borrowers can also choose a piggy-back 1st and 2nd on new loan purchases, should the blended rate make more sense than just a new 1st TD. In the first 2nd TD program of its kind, ITIN borrowers are also included in this offering.

In its second September debut, LoanStream will now offer proprietary 1:0 (rate reduced 1% below the note rate for year 1) and 2:1 (rate reduced 2% below the note rate for year 1 and 1% below for year 2) temporary buy-down programs, similar to those allowed by agency and government loan programs. With temporary buy-down loans, sellers may use allowed concessions to fund the temporary buy-down escrow accounts that subsidize the payments for either one or two years. Better yet, there is no LLPA (loan-level price adjustment) charged to the consumer. Borrowers are still qualified on the fully indexed/amortized rate to ensure ability to repay and ATR requirements. ITIN borrowers are also included in this offering.

Being one of the first companies to re-enter the non-agency space in 2014, LoanStream Mortgage operates as a private prime and government mortgage company, with a strong secondary appetite for non-qualified mortgage products (NonQM). While the company will continue its grassroots in prime and government lending, Serene Vernon, the company's President, said, "While many of the prime eligible borrowers were purchasing and refinancing during 2020-2021, those self-employed, real estate investor and jumbo loan size consumers, were largely locked out of the market. Now is the time to turn our attention to these borrowers and offer them the financing they need."

The company operates Wholesale under LoanStream Mortgage, Forward Lending and Lending Pro's, providing brokers many ways to access financing for these and many other great loan programs.

Bankers can access delegated, non-delegated, bulk, flow, mandatory and best-effort lock options through Loan Stream's Correspondent channel.

Contact Information:

Thomas Shaw
Chief Marketing Officer
tshaw@lsmortgage.com
949.679.4268

Serene Vernon
President
svernon@lsmortgage.com
949.679.7400

SOURCE: LoanStream Mortgage

.

View source version on accesswire.com:
https://www.accesswire.com/780948/loanstream-continues-to-break-barriers-and-releases-new-proprietary-products

© 2023 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.